Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 29;13(3):673-677.
doi: 10.21037/tlcr-23-735. Epub 2024 Mar 15.

Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure?

Alexander I Salter  1 , Millie Das  1   2
Affiliations
Editorial

Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure?

Alexander I Salter et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Neoadjuvant non-small cell lung cancer (neoadjuvant NSCLC); cancer immunotherapy; platform trial.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-735/coif). A.I.S. is an inventor of patents related to cancer immunotherapy, some of which have been licensed to Lyell Immunopharma. M.D. has participated in advisory boards for Advarra, Astra Zeneca, Bristol Myer Squibb, Catalyst Pharmaceuticals, Gilead, Guardant, Janssen, Novocure, Regeneron, Genzyme and Sanofi; has provided consulting services for Eurofins, Abbvie, and Janssen; has received institutional grant funding from Merck, Genentech, CellSight, Novartis, Varian, and Verily; is the President of the Association of Northern California Oncologists; and has received travel funds and honoraria for speaking at various meetings related to cancer immunotherapy (Plexus, IDEO, Springer, Medical Educator Consortium, Dedham Group, DAVA Oncology, MJH Healthcare Holdings, ANCO, Aptitude Health, Med Learning Group, Curio, and Triptych Health). The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Trial schema for NeoCOAST and NeoCOAST-2. 1, neoadjuvant immunotherapy in the NeoCOAST trial consisted of durvalumab alone, or durvalumab combination with either oleclumab, monalizumab, or danvatirsen. Durvalumab was dosed at 1,500 mg once, oleclumab dosing was dosed at 3,000 mg every 2 weeks, monalizumab was dosed at 750 mg every 2 weeks, and danvatirsen was dosed at 200 mg every week (including a 7-day lead-in period of danvatirsen 200 mg on days 1, 3, and 5 of week 0). 2, neoadjuvant chemoimmunotherapy in the NeoCOAST-2 trial consists of durvalumab + oleclumab + platinum-based chemotherapy, durvalumab + monalizumab + chemotherapy, or volrustomig + chemotherapy. Volrustomig is a PD-1/CTLA-4 bi-specific antibody. 3, adjuvant immunotherapy in the NeoCOAST-2 trial consists of durvalumab in combination with either oleclumab, monalizumab, or volrustomig, started within 10 weeks of surgical resection and continuing for up to 1 year or until disease progression per RECIST v1.1 criteria. NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; CTLA-4, cytotoxic T lymphocyte protein 4; RECIST, Response Evaluation Criteria in Solid Tumors.
See this image and copyright information in PMC

Comment on

References

    1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9. 10.1038/nature10673 - DOI - PMC - PubMed
    1. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71. 10.1038/nature13954 - DOI - PMC - PubMed
    1. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 2020;10:727-42. - PMC - PubMed
    1. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:1919-29. 10.1056/NEJMoa1709937 - DOI - PubMed
    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed